FDA Clears Investigational New Drug Application for Phase Ib/IIa Trial of CK0802 in Steroid-Refractory Graft-Versus-Host Disease

Key Takeaways

• FDA IND clearance launches Phase Ib/IIa CK0802 trial for steroid‑refractory GVHD
• Primary endpoint: Day‑29 overall response rate, safety focus, data due early 2027
• CK0802 uses off‑the‑shelf cord‑blood Tregs, no HLA matching, three‑year shelf life
• Mechanism: IL‑10 secretion, IL‑2 cytokine sink, APC modulation to restore tolerance
• Earlier COVID‑19 ARDS trial showed reduced hyperinflammation, supporting cross‑indication efficacy

Pulse Analysis

Steroid‑refractory graft‑versus‑host disease remains one of the most lethal complications after allogeneic stem‑cell transplantation, with roughly half of patients developing GVHD and only about 30% surviving two years when steroids fail. Conventional second‑line agents, such as calcineurin inhibitors or extracorporeal photopheresis, carry significant toxicity and often deliver modest durability. The unmet clinical gap has spurred intense interest in cellular immunotherapies that can restore immune equilibrium without broad immunosuppression, positioning CK0802 at the forefront of a new therapeutic class.

CK0802 distinguishes itself through an off‑the‑shelf design that leverages cord‑blood‑derived regulatory T cells engineered to thrive in the inflammatory milieu of acute GVHD. By secreting IL‑10, acting as an IL‑2 cytokine sink, and dampening antigen‑presenting‑cell activation, the product aims to re‑educate the host immune system rather than merely suppress it. Its manufacturing platform eliminates the need for patient‑specific HLA matching and offers a three‑year shelf life, addressing logistical hurdles that have hampered autologous cell therapies. The prior COVID‑19 ARDS trial, which demonstrated reduced hyperinflammation and improved survival signals, provides early proof‑of‑concept that the platform can modulate diverse cytokine storms.

The FDA’s IND clearance not only validates Cellenkos' preclinical and manufacturing data but also signals regulatory confidence in the safety profile of allogeneic Treg products. If the Phase Ib/IIa trial confirms safety and early efficacy, CK0802 could accelerate to pivotal studies, attracting interest from transplant centers seeking rapid, scalable interventions. Successful commercialization would likely reshape reimbursement models for cell‑based therapies, encouraging broader adoption of off‑the‑shelf immunomodulators across hematology and beyond.